이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Effects of PosBion® Supplementation on Intestinal Barrier Function in Adults With Irritable Bowel Syndrome

2026년 11월 12일 업데이트: My Myracle Sdn.Bhd

Effects of PosBion® Supplementation on Barrier-Related Biomarkers in Adults With Irritable Bowel Syndrome

Postbiotic metabolites produced by beneficial bacteria may influence inflammatory responses, mucosal immunity, and host physiological signalling. PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11, derived from Lactiplantibacillus plantarum RS5 and RI11, respectively.

This study will evaluate changes in a panel of salivary biomarkers following 12 weeks of PosBion® supplementation in adults with irritable bowel syndrome (IBS). The biomarkers include myeloperoxidase (MPO), zonulin, lipopolysaccharide (LPS), LPS-binding protein (LBP), cortisol, serotonin, secretory immunoglobulin A (sIgA), lactoferrin, interleukin-8 (IL-8), immunoglobulin E (IgE), immunoglobulin M (IgM), and immunoglobulin G (IgG).

The study will primarily evaluate changes in inflammatory activity, while additional biomarkers will be used to explore mucosal immune, neuroendocrine, immunoglobulin, microbial exposure, and barrier-related responses following supplementation.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

상세 설명

Irritable bowel syndrome is a disorder of gut-brain interaction associated with complex alterations in immune activity, gastrointestinal physiology, microbial-host interactions, and mucosal function. Microbial metabolites derived from beneficial bacteria have received increasing attention because of their potential immunomodulatory, anti-inflammatory, antioxidant, and mucosal effects.

PosBion® is a commercially available dietary supplement containing LPM5 and LPM11, proprietary cell-free metabolite preparations derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. The finished preparations do not contain viable or inactivated bacterial cells.

Previous experimental investigations of RS5- and RI11-derived metabolites have demonstrated antimicrobial, antioxidant, immunomodulatory, and intestinal health-related activities. In particular, RI11-derived metabolites have been associated experimentally with modulation of inflammatory cytokines, antioxidant defence, and barrier-associated pathways.

The present study is designed as a prospective, single-arm, open-label interventional study to investigate longitudinal changes in salivary biomarkers following 12 weeks of PosBion® supplementation.

The principal biomarker of interest will be salivary IL-8 as a marker of inflammatory activity. Additional inflammatory markers will include MPO and lactoferrin. Mucosal and adaptive immune responses will be evaluated using sIgA, IgE, IgM, and IgG. Cortisol and serotonin will be investigated as neuroendocrine biomarkers.

Salivary zonulin, LPS, and LBP will also be assessed as exploratory biomarkers potentially related to microbial exposure and barrier-associated processes. Because these biomarkers are measured in saliva, they will not be interpreted as direct measurements of intestinal permeability.

Unstimulated saliva will be collected at baseline and after 4, 8, and 12 weeks of supplementation under standardized collection conditions. Biomarker concentrations will be quantified using commercially available validated assays according to the manufacturers' instructions.

The study is intended to provide mechanistic biomarker data on the biological responses associated with PosBion® supplementation rather than to evaluate changes in IBS symptom severity.

연구 유형

중재적

등록 (추정된)

55

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 이상 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

아니

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Adults aged 18 years or older
  • Experienced one or more symptoms suggestive of irritable bowel syndrome (IBS) prior to enrolment
  • Willing to comply with interventional plan
  • Willing to give consent

Exclusion Criteria:

  • History of chronic or serious medical conditions, including diabetes mellitus, cardiovascular disease, chronic kidney disease, cancer, or chronic respiratory disease
  • Current use of gastrointestinal health supplements
  • Current use of antibiotics or antiviral medications
  • Current use of probiotic, prebiotic, or postbiotic supplements
  • Major surgery within the previous 6 months.
  • Pregnant or lactating woman

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 지지 요법
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: PosBion® Supplementation

Subjects will consume PosBion® for 12 consecutive weeks. Two sachets will be consumed daily, with one sachet taken after breakfast and one sachet after dinner. Saliva samples will be collected at baseline and Weeks 4, 8, and 12 for biomarker analysis.

PosBion® contains the proprietary cell-free metabolite preparations LPM5 and LPM11 derived from Lactiplantibacillus plantarum RS5 and RI11, respectively. Each sachet contains 2,500 mg LPM5 and 2,500 mg LPM11. Subjects will consume two sachets daily for 12 weeks, with one sachet taken after breakfast and one after dinner. The finished preparations do not contain viable or inactivated bacterial cells.

다른 이름들:
  • PosBion®

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Change in Salivary Interleukin-8 (IL-8) Concentration
기간: Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12

Salivary IL-8 concentration will be quantified using an enzyme-linked immunosorbent assay (ELISA). Changes over time will be evaluated, with the principal comparison between baseline and Week 12.

Baseline, Week 4, Week 8, and Week 12; primary comparison: baseline to Week 12
Change in Salivary Myeloperoxidase (MPO)
기간: Baseline, Week 4, Week 8, and Week 12

Salivary MPO concentration will be quantified using ELISA as a marker associated with neutrophil and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lactoferrin
기간: Baseline, Week 4, Week 8, and Week 12

Salivary lactoferrin concentration will be quantified using ELISA as a marker associated with mucosal innate immune and inflammatory activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Secretory Immunoglobulin A (sIgA)
기간: Baseline, Week 4, Week 8, and Week 12

Salivary sIgA concentration will be quantified as a marker of mucosal immune activity.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgE
기간: Baseline, Week 4, Week 8, and Week 12

Salivary IgE concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgM
기간: Baseline, Week 4, Week 8, and Week 12

Salivary IgM concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary IgG
기간: Baseline, Week 4, Week 8, and Week 12

Salivary IgG concentration will be quantified to evaluate changes in the immunoglobulin profile following supplementation.

Baseline, Week 4, Week 8, and Week 12

2차 결과 측정

결과 측정
측정값 설명
기간
Baseline, Week 4, Week 8, and Week 12
기간: Baseline, Week 4, Week 8, and Week 12

Salivary cortisol concentration will be quantified as a neuroendocrine biomarker associated with physiological stress responses.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Serotonin
기간: Baseline, Week 4, Week 8, and Week 12

Salivary serotonin concentration will be quantified as an exploratory neuroendocrine biomarker.

Baseline, Week 4, Week 8, and Week 12

기타 결과 측정

결과 측정
측정값 설명
기간
Change in Salivary Zonulin
기간: Baseline, Week 4, Week 8, and Week 12

Salivary zonulin will be quantified as an exploratory biomarker potentially associated with barrier-related processes. The measurement will not be considered a direct assessment of intestinal permeability.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary Lipopolysaccharide (LPS)
기간: Baseline, Week 4, Week 8, and Week 12

Salivary LPS concentration will be evaluated as an exploratory marker of microbial exposure. Changes will not be interpreted as direct evidence of intestinal microbial translocation.

Baseline, Week 4, Week 8, and Week 12
Change in Salivary LPS-Binding Protein (LBP)
기간: Baseline, Week 4, Week 8, and Week 12

Salivary LBP concentration will be evaluated as an exploratory biomarker related to host responses to microbial products.

Baseline, Week 4, Week 8, and Week 12

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 11월 15일

기본 완료 (추정된)

2027년 2월 15일

연구 완료 (추정된)

2027년 3월 15일

연구 등록 날짜

최초 제출

2026년 11월 12일

QC 기준을 충족하는 최초 제출

2026년 11월 12일

처음 게시됨 (실제)

2026년 11월 18일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 18일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 12일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

기타 연구 ID 번호

  • POSTBION-LEAKY GUT

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

예

IPD 계획 설명

De-identified individual-level data underlying the reported study findings, together with relevant data dictionaries, may be made available to qualified researchers following publication.

IPD 공유 기간

Beginning approximately 6 months after publication of the primary study findings and available for up to 5 years.

IPD 공유 액세스 기준

Data may be provided to qualified researchers who submit a scientifically sound proposal. Requests will be reviewed by the principal investigator and/or study sponsor. Approved access may require a data-use agreement and secure transfer of de-identified data.

IPD 공유 지원 정보 유형

  • 연구_프로토콜
  • 수액
  • CSR

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .